

EP0945512

Publication Title:


Novel serine proteases

Abstract:

Abstract of EP0945512

Polypeptides having the amino acid sequences listed as SEQ.NO.13 and 14 or those amino acid sequences modified by deletion, addition, substitution or a combination thereof of one or more amino acids in said amino acid sequence, and having serine protease activity; DNA coding therefor; and a method for producing the polypeptides using the DNA. Data supplied from the esp@cenet database - Worldwide

Courtesy of <http://v3.espacenet.com>



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 0 945 512 A2**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
29.09.1999 Bulletin 1999/39

(51) Int Cl.⁶: **C12N 15/57**, C12N 9/64,
C12N 1/21, C12N 5/10,
C07K 16/40, C12Q 1/37

(21) Application number: **99301053.7**

(22) Date of filing: **15.02.1999**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**
Designated Extension States:
AL LT LV MK RO SI

- Mitsui, Shinichi
Kyoto-shi, Kyoto (JP)
- Yamaguchi, Nozomi
Karamaguchi-tori, Kita-ku, Kyoto-shi (JP)

(30) Priority: **13.02.1998 JP 3148798**

(74) Representative: **Stoner, Gerard Patrick et al
MEWBURN ELLIS
York House
23 Kingsway
London WC2B 6HP (GB)**

(72) Inventors:
• **Tsuruoka, Nobuo**
Ibaraki-shi, Osaka (JP)
• **Yamashiro, Kyoko**
Takatsuki-shi, Osaka (JP)

Remarks:

The applicant has subsequently filed a sequence listing and declared, that it includes no new matter.

(54) **Novel serine proteases**

(57) Polypeptides having the amino acid sequences listed as SEQ.NO.13 and 14 or those amino acid sequences modified by deletion, addition, substitution or

a combination thereof of one or more amino acids in said amino acid sequence, and having serine protease activity; DNA coding therefor; and a method for producing the polypeptides using the DNA.

EP 0 945 512 A2

Description

[0001] The present invention relates to novel serine proteases, DNA coding therefor and a method for producing the serine proteases, as well as to a screening method for physiologically active substances using the serine proteases or DNA coding therefor, and a drug therapy application using DNA fragments which suppress expression of the novel serine proteases.

BACKGROUND

[0002] Serine proteases are known to be widely present in animals, plants and microorganisms, and in particularly they are known to be involved in many biological reactions in higher animals, including food digestion, blood coagulation and fibrinolysis, complement activation, hormone production, ovulation and fertilization, phagocytosis, cell proliferation, development and differentiation, aging, cancer metastasis, etc. (Neurath, H. Science, 224, 350-357, 1984). Recently it has been confirmed that serine proteases also act as physiologically important functional molecules in the central nervous system.

[0003] Serine proteases in the brain are believed to be not only involved in the promotion of neurite outgrowth of neurons, but are also to be involved in the process of synapse formation with target neurons (Liu, Y., Fields, R.D., Fitzgerald, S., Festoff, B.W., and Nelson, P.G., J. Neurobiol., 25, 325-, 1994). For example, it is known that both tissue (tPA) and urokinase (uPA) plasminogen activator (PA) are expressed in the brain, and experiments using cultured nerve cells have been reported which show that PA induces extension of neurite outgrowth (Pittman, R.N., Ivins, J.K. and Buettner, H.M., J. Neurosci., 9, 4269, 1989).

[0004] Experiments using cultured nerve cells have also shown that thrombin, which has also been confirmed to be expressed in the brain, contributes to the inhibitory effect of neurite extension in counteraction to PA (Dihanich, M., Kaser, M., Reinhard, E., Cunningham, D. and Monard, D., Neuron, 6, 575, 1991). Since thrombin receptor, that span the membrane seven times and coupled to G-Proteins, is expressed widely throughout the brain, and the inhibitory effect of thrombin on neurite extension also occurs by the amino-terminal peptides (tethered ligand) of the receptor with agonist activity, the inhibitory effect of thrombin on neurite outgrowth is believed to be a receptor-mediated specific response.

[0005] Elsewhere it has been reported that serine protease inhibitors (serpins) are also expressed in the brain, such as protease nexin I, for example, which acts as a powerful thrombin inhibitor preventing cellular death of motor neurons. It has also been reported that in some Alzheimer (AD) patients the amount of the α 1-antichymotrypsin as a serpin is increased in the cerebrospinal fluid, while conversely the amount of protease nexin I which is also a serpin is reduced in the cerebrospinal fluid.

[0006] Such facts indicate a clear upset of the quantitative balance between serine proteases and serpins in the brains of AD patients. In particular, since the reduced amount of protease nexin I which is a powerful thrombin inhibitor would be expected to produce a state of relatively accelerated thrombin activity in the brain, this suggests that part of the pathological condition of AD patients is due to the inhibitory effect of thrombin on neurite outgrowth.

[0007] Based on these results, it may be concluded that the various neurodegenerative diseases involve imbalance in the serine proteases and serine protease inhibitors in the brain. Consequently, a therapy which controls such imbalance is necessary in these neurodegenerative disorders. However, it has been very difficult to explain all of the pathological conditions of neurodegenerative diseases in terms of only the presently known serine proteases among all of the serine proteases which are expressed and carry out important physiological functions in the brain. Also, while it is expected that numerous other serine proteases exist which are expressed in the brain and carry out important physiological functions, most of them have not yet been identified.

[0008] The present invention was accomplished in light of these circumstances, and its object is to provide DNA coding for novel serine proteases as well as the novel serine proteases themselves. It is a further object of the invention to provide a method for suppressing expression of the novel serine proteases by the antisense method using a fragment of the DNA, as well as a method of producing the serine proteases in large amounts and a method of screening for inhibitors of the serine proteases using the DNA, and to provide an assay system using specific antibodies for the serine proteases.

[0009] As a result of much diligent research, the present inventors have obtained full length cDNA coding for two different novel serine proteases, by direct isolation of cDNA coding for serine protease proteins expressed in the brain from human brain-derived mRNA by reverse transcription polymerase chain reaction (RT-PCR). We have also succeeded in expressing cDNA coding for the serine protease proteins in animal cells to achieve expression of the mature proteins, and have thus completed the present invention.

[0010] The present invention therefore provides a polypeptide having the amino acid sequence shown in SEQ. ID. NO:13 or an amino acid sequence modified by deletion, addition and/or substitution of one or more amino acids and having serine protease activity; a polypeptide having the amino acid sequence shown in SEQ. ID. NO:14 or an amino

acid sequence modified by deletion, addition and/or substitution of one or more amino acids and having serine protease activity; and partial peptides thereof.

[0011] The present invention further provides a polypeptide encoded by naturally occurring DNA which hybridizes with DNA having the nucleotide sequence shown in SEQ. ID. NO:11 under stringent conditions, which has serine protease activity; a polypeptide encoded by naturally occurring DNA which hybridizes with DNA having the nucleotide sequence shown in SEQ. ID. NO:12 under stringent conditions, which has serine protease activity; and partial peptides thereof.

[0012] The present invention still further provides DNA coding for the aforementioned polypeptides, or fragments thereof. The DNA or fragments thereof are useful for producing the polypeptides or partial peptides thereof, and the DNA or fragments thereof are also useful for suppressing expression of serine proteases by the antisense method.

[0013] The present invention still further provides a vector, especially an expression vector, comprising the aforementioned DNA or its fragment, and a host transformed by the vector.

[0014] The present invention still further provides a method of producing the aforementioned polypeptides or partial peptides, which is characterized by culturing or breeding the aforementioned host and collecting the serine proteases or partial peptides thereof.

[0015] The present invention still further provides antibodies against the aforementioned polypeptides.

[0016] The present invention still further provides a screening method for physiologically active substances, using the aforementioned polypeptides or partial peptides thereof or the aforementioned DNA or fragments thereof.

DETAILED DESCRIPTION

[0017] cDNA was synthesized from commercially available human brain-derived poly(A)+RNA, and subjected to PCR using a primer designed based on the serine protease motif. The resulting PCR product was sequenced, and cDNA fragments coding for novel serine proteases were obtained. The 5' end sequences and 3' end sequences were extended based on the obtained sequence data to elucidate the primary structure of the cDNA coding for the novel serine proteases.

[0018] It was then attempted to isolate the full length cDNA by the PCR method based on the elucidated structure. As a result, two types of cDNA were successfully isolated, and were designated as human SP66 type 1 and human SP66 type 2. Human SP66 type 1 and human SP66 type 2 were both shown to code for novel serine proteases. Examples 1, 2 and 3 are provided as concrete examples. The present inventors then used COS-1 cells to express the mature protein encoding the human SP66 type 1 and human SP66 type 2 cDNA, and confirmed that they were in fact functional proteins with enzyme activity. Example 4 is provided as a concrete example.

[0019] These results demonstrated that the isolated human SP66 type 1 and human SP66 type 2 coded for novel serine proteases which were not only novel in their primary structure but also were actually functional proteins with enzyme activity.

[0020] Since the novel serine proteases of the invention are functional proteins with enzyme activity, they carry out specific roles for physiological function in the brain through their enzyme activity. For the various neurodegenerative diseases where there is an imbalance between serine proteases and serine protease inhibitors in the brain, these serine proteases may be supplemented or expression of the serine proteases may be suppressed, in order to normalize the balance between serine proteases and serine protease inhibitors in the brain, as an effective method of medical treatment.

[0021] As particular treatments there may be mentioned intraventricular administration and forced expression by gene therapy as supplementation treatments, which would be based on increasing intracerebral levels for improvement of dementia. Also possible are inhibition therapies based on inhibiting agents created by using the cDNA or a fragment described in the present application to express a gene recombinant and screening for inhibitors. The cDNA of the present application may also be applied in gene therapy using antisense inhibition methods since it is characterized by being human-derived.

[0022] Furthermore, monitoring the balance between serine proteases and serine protease inhibitors in the brain is important for diagnosis of various neurodegenerative diseases and pathological analysis, which includes biochemical examinations, and this can be accomplished by quantifying the amount of the novel serine proteases of the invention in body fluids, and especially the cerebrospinal fluid. For example, by measuring the amount of the novel serine proteases of the invention in the cerebrospinal fluid it is possible to determine the amelioration or progression of dementia, and therefore the present invention also provides specific antibodies for the novel serine proteases of the invention and clinical examination kits for their measurement to determine therapeutic effects. In addition, since quantifying the amounts of the novel serine proteases of the invention in cerebrospinal fluid can serve to determine amelioration or progression of dementia, a major contribution is thus provided toward the development of drug treatments for diseases for which no method of treatment exists, such as Alzheimer's disease.

[0023] The present invention will now be explained in greater detail.

[0024] According to the invention there are disclosed the nucleotide sequences shown in SEQ. ID. NO:11 and SEQ. ID. NO:12 as nucleotide sequences of DNA coding for the novel serine proteases of the invention, but the DNA of the serine proteases of the invention is not necessarily restricted to them. Once the amino acid sequence of a natural serine protease has been determined, different nucleotide sequences coding for the same amino acid sequence can be designed and modified based on degeneration of the code. In such cases, a preferred embodiment is one which uses codons which are utilized with a high frequency by the intended host.

[0025] DNA coding for the natural-type serine proteases of the invention may be obtained in a manner of preparing cDNA such as described in the examples, but is not limited to this. In other words, DNA coding for the amino acid sequences of the natural serine proteases may be cloned as cDNA by a different strategy than the strategy specifically disclosed by the present invention, and it may also be cloned from the genome of cells which produce it.

[0026] The cloning may be accomplished by, for example, hybridization from a brain cDNA library. The DNA of the invention may also include DNA which codes for a protein or glycoprotein with serine protease activity and which hybridizes with the nucleotide sequence of SEQ. ID. NO:11 or SEQ. ID. NO:12 under stringent conditions. Such DNA is preferably naturally occurring cDNA or genomic DNA, and it may be human-derived DNA, for example. Common methods for hybridization are well known among those skilled in the art (such as Jikken Igaku Rinji Special Issue, Yodosha, Biotechnology Experiment Methods Series, Genetic Engineering Overview, Vol.5, No.11, 24-60, 1987; Current Protocols in Molecular Biology, John Wiley & Sons, Chap.6, 1995), and methods for measuring activity are also well known among those skilled in the art.

[0027] When cloning from a genome, the different primer nucleotides or probe nucleotides used in the examples may be used as probes for selection of genomic DNA fragments. Other probes may also be used which are designed based on the nucleotide sequences listed as SEQ. NO.11 and SEQ. NO.12. Common methods for cloning desired DNA from genomes are well known among those skilled in the art (Current Protocols In Molecular Biology, John Wiley & Sons, Chaps. 5 and 6, 1995).

[0028] DNA coding for the natural serine proteases of the invention can also be prepared by chemical synthesis. Chemical synthesis of DNA can be easily accomplished by a person skilled in the art using an automatic DNA synthesizer, such as the 396 DNA/RNA synthesizer by Applied Biosystems Co. Thus, a person skilled in the art can easily synthesize DNA having the nucleotide sequence shown in SEQ. ID. NO:11 or SEQ. ID. NO:12.

[0029] DNA which codes for naturally occurring serine proteases according to the invention with codons other than the original codons can be prepared by chemical synthesis as described above, and can be obtained by a conventional method such as site-directed mutagenesis using DNA or RNA with the nucleotide sequence shown in SEQ. ID. NO:11 or SEQ. ID. NO:12 as a template together with a mutagenic primer, according to a common method (see, for example, Current Protocols in Molecular Biology, John Wiley & Sons, Chap.8, 1995).

[0030] Once the amino acid sequence has been thus determined, it is possible to design and produce various different mutant serine proteases, such as polypeptides with one or more amino acid additions to the natural amino acid sequence which also maintain serine protease activity, polypeptides with one or more amino acid deletions from the natural amino acid sequence which also maintain serine protease activity, polypeptides with one or more substitutions of other amino acids for amino acids in the natural amino acid sequence which also maintain serine protease activity, and polypeptides with mutations involving combinations of amino acid addition mutations, amino acid deletion mutations and amino acid substitution mutations, which also maintain serine protease activity.

[0031] These may be prepared by the following method or by a peptide synthesis method which is known or by cleavage of the serine protease with an appropriate protease. Mutant serine proteases which maintain the serine protease activity of the invention or DNA coding therefor may also be prepared in the same manner.

[0032] There is no particular restriction on the number of amino acids involved in the addition, deletion or substitution of amino acids, and for additions it will be determined based on the purpose of the mutation, i.e. it will depend on the number of amino acids of a functional protein used as a hybrid protein with the serine protease of the invention, such as a protein for publicly known extraction and purification or stabilization (for example, maltose binding protein) or any of various physiologically active proteins, or on the number of amino acids of a signal peptide added to the serine protease. For example, 1 to 50, and preferably 1 to 10 additions may be made.

[0033] For deletions, the number of amino acids deleted may be for example 1 to 30, and preferably 1 to 20, as designed and determined for maintaining serine protease activity, or may be a number of amino acids in a region outside of the activity range of the serine protease. For substitutions, the number of substituted amino acids may be for example 1 to 10, and preferably 1 to 5, as designed and determined for maintaining serine protease activity.

[0034] It is preferred for the aforementioned mutated and modified serine proteases to have for example at least 70%, preferably at least 80% and more preferably at least 90% homology with the original amino acid sequences shown in SEQ. ID. NOS:13 and 14.

[0035] When DNA for a serine protease or mutant serine protease according to the invention has been obtained in this manner, it may be used to produce a gene recombinant serine protease or a gene recombinant mutant serine protease by any common method. Specifically, DNA coding for the serine protease or mutant serine protease of the

invention may be inserted into an appropriate expression vector, the expression vector then introduced into appropriate host cells, the host cells then cultured and the desired serine protease or mutant serine protease collected from the obtained culture (cells or medium).

[0036] The serine protease or mutant serine protease of the invention may also be obtained in a biochemically modified form, for example by N-terminal acylation and C1-6 acylation, including formylation and acetylation, or in a deleted form. The expression system may be designed for secretion efficiency and expression volume by addition or improvement of the signal sequence or selection of the host. Means for addition and improvement of signal sequences include linkage of a gene coding for the signal peptide of another structural peptide upstream of the 5' end of the serine protease or mutant serine protease structural general of the invention, via a gene coding for a cleavable partial peptide. As a specific example there may be mentioned a method using the signal sequence of the trypsin gene mentioned in Example 4 and a gene coding for an enterokinase-recognizing sequence.

[0037] A eukaryotic or prokaryotic organism may be used as the host. Prokaryotic organisms which may be used include bacteria, especially *Escherichia coli* and *Bacillus* bacteria such as *B. subtilis*. Eukaryotic organisms which may be used include yeast, for example *Saccharomyces* yeast such as *S. cerevisiae* and other eukaryotic microorganisms, as well as insect cells such as *Spodoptera frugiperda*, *Trichoplusia ni*, *Bombyx mori*, and animal cells such as human cells, simian cells, mouse cells and the like, particularly COS cells, Vero cells, CHO cells, L cells, C127 cells, BALB/c 3T3 cells and Sp-2/O cells.

[0038] The expression vector used may be a plasmid, phage, phagemid, virus (baculo (insect) or vaccinia (animal cells)), etc. The promoter in the expression vector is selected based on the host cells; examples of bacterial promoters include lac promoter and trp promoter, and examples of yeast promoters include adhI promoter and p_{gk} promoter.

[0039] Insect promoters include baculovirus polyhedrin promoter, etc. and for animal cells the Simian Virus 40 early or late promoter, CMV promoter, HSV-TK promoter or SR α promoter may be mentioned. A preferred embodiment of the expression vector is one which further includes an enhancer, a splicing signal, a polyA addition signal, a selection marker (for example, a dihydrofolate reductase gene (methotrexate resistance) and a neo gene (G418 resistance)). When an enhancer is used, an SV40 enhancer, for example, may be inserted upstream or downstream of the gene.

[0040] Transformation of the host with the expression vector may be accomplished by a common method well known to those skilled in the art, and such methods are described for example in Current Protocols In Molecular Biology, John Wiley & Sons, 1995. The transformants may also be cultured according to common methods. purification of the serine protease or mutant serine protease from the cultured product may be accomplished according to common methods for isolation and purification of proteins, for example by ultrafiltration and different types of column chromatography, such as chromatography using Sepharose (Pharmacia Biotechnologies).

[0041] Because the serine protease or mutant serine protease of the invention obtained in this manner is a functional protein with enzyme activity, it can serve as a useful means for pathological analysis, and allows screening of physiologically active substances using the protein, by screening methods which are useful for investigational research on treatment drugs for various diseases.

[0042] As for one example of such screening methods there can be used to measure the physiological activity of test samples of peptides, proteins, non-peptide compounds, synthetic compounds and fermentation products, as well as of natural components which are obtained from culture supernatants and artificial components including various synthetic compounds.

[0043] Preferred embodiments of the screening method of the invention also include the aforementioned physiological activity measurement, as well as binding affinity assays, which employ DNA coding for the serine protease or partial peptide thereof or mutant serine protease or partial peptide thereof according to the invention, or a host transformed thereby or its cell membrane fraction (see Shinkiso Seikagaku Jikkenho 6, Assay Methods Using Biological Activity, ed. Nakajima, T., Nomoto, A., Matsushashi, M., Miura, K., Muramatsu, M., Maruzen, KK., 1988).

[0044] That is, a screening method for physiologically active substances using a serine protease or its partial peptide according to the invention is carried out by screening a test sample using a serine protease or its partial peptide according to the invention, DNA coding therefor, or host cells or their cell membrane fraction containing the serine protease or its partial peptide. A specific method may be carried out by an enzyme activity assay (such as the modified method described in Example 4) or binding affinity assay using a substrate for the serine protease or its partial peptide according to the invention, for example a color-development substrate or other synthetic substrate, or a substrate labelled with a radio isotope.

[0045] When using host cells containing the serine proteases or their partial peptides, the cells may be immobilized by a publicly known method (with a reagent for example glutaraldehyde, formaldehyde, etc.). When using DNA coding for the proteases or their partial peptides, the accelerated or suppressed gene expression may be evaluated using a reporter gene, such as luciferase.

[0046] The aforementioned cell membrane fraction is the fraction containing most of the cell membrane, obtained by culturing host cells capable of expressing DNA coding for the serine protease or its partial peptide according to the invention under conditions suitable for expression, and then disrupting the host cells containing the serine protease or

its partial peptide by a publicly known method.

[0047] The serine protease or its partial peptide or mutant serine protease or its partial peptide according to the invention, or DNA coding therefor, may also be provided in the form of a kit for use when carrying out the above-mentioned screening method.

[0048] In particular, since the serine proteases of the invention and DNA coding therefor are characterized by being human-derived, DNA coding for the serine protease or its partial peptide according to the invention may be used to produce a gene recombinant which may be directly administered to humans, for use as a supplementation treatment. DNA coding for a serine protease or its partial peptide according to the invention may also be administered directly to humans as a gene expression inhibiting treatment by the antisense method (Progress in Nucleic Acid Research and Molecular Biology, vol.44, p143-166, ed. by Cohn, W.E. and Moldave, K., "Cell Delivery and Mechanisms of Action of Antisense Oligonucleotides", Academic Press, Inc., 1993).

[0049] As partial peptides there may be mentioned serine protease fragments comprising regions unique to the serine proteases of the invention, such as peptide fragments present near the serine residues of the active sites and peptide fragments which can serve as recognition sites for antibodies specific to the serine proteases or mutated serine proteases of the invention. Such partial peptides can be prepared by the aforementioned methods for the serine proteases or mutated serine proteases of the invention or a publicly known peptide synthesis method, or by cleavage of the serine proteases or mutated serine proteases with appropriate proteases.

[0050] A partial peptide obtained in this manner may be bound to a carrier protein and then used to immunize a rabbit, mouse, rat, goat, chicken, guinea pig or other animal by a common method to obtain antiserum (polyclonal antibodies). Monoclonal antibodies may also be prepared by using a common method to immunize mice, rats or other animals and fusing the cells with myeloma cells to produce hybridomas (see Shinkiso Seikagaku Jikkenho 6, Assay Methods Using Biological Activity, ed. Nakajima, T., Nomoto, A., Matsushashi, M., Miura, K., Muramatsu, M., Maruzen, KK., 1988).

[0051] In addition, DNA for the aforementioned serine proteases or mutant serine proteases may be used to produce gene recombinant serine proteases or gene recombinant mutant serine proteases which are then used to prepare polyclonal antibodies or monoclonal antibodies by similar methods.

[0052] Furthermore, the polyclonal antibodies or monoclonal antibodies obtained in this manner can be used for assay of the serine proteases of the invention in human body fluids, to allow pathological analyses including diagnoses and biochemical examinations for various neurodegenerative diseases.

EXAMPLES

[0053] The present invention will now be explained in fuller detail by way of examples.

Example 1. RT-PCR using serine protease-conserved region

[0054] Human brain poly(A)+RNA (Code No. CL6516-1) purchased from Clontech Co. was used for RT-PCR with the serine protease-conserved region. That is, 2 µl (1 µg) of oligo dT primer was added to 5 µl (about 6 µg) of mRNA, and after heating at 70°C for 10 minutes the mixture was cooled on ice. To this heat-denatured mRNA there were added 4 µl of 5 x first-strand buffer solution (250 mM Tris/HCl, pH 8.3, 375 mM KCl, 15 mM MgCl₂), 1 µl of 10 mM dNTP, 2 µl of 0.1 M DTT, distilled water treated with diethylpyrocarbonate (DEPC) and 5 µl (1000 U) of SuperScript II RT, and reaction was conducted at 37°C for one hour.

[0055] The first strand cDNA obtained in this manner was used as a template for PCR with the serine protease-conserved region. The primers used were the oligomer 5' GTG CTC ACN GCN GCB CAY TG 3' shown in SEQ. ID. NO: 1 synthesized based on the amino acid-conserved region (N-Val-Leu-Thr-Ala-Ala-His-Cys) near an active residue (His) and the oligomer 5' AGC GGN CCN CCD SWR TCV CC 3' shown in SEQ. ID. NO: 2 synthesized based on the amino acid-conserved region (N-Gly-Asp-Ser-Gly-Gly-Pro-Leu) near an active residue (Ser). Taq DNA polymerase (Amersham Co.) was used for PCR, after which the PCR reaction solution was subcloned in a pCR II vector (Invitrogen Co.). Sequencing of the resulting PCR product by a common method confirmed a cDNA fragment coding for a novel serine protease.

Example 2. Obtaining 5' end and 3' end sequences

Step 1. cDNA synthesis

[0056] A 5 µl (approximately 5 µg) portion of the same human brain poly(A)+RNA in Example 1 was used to synthesize template cDNA. Specifically, after adding 2 µl (1 µg) of oligo dT adapter primer and heating at 70°C for 10 minutes, the mixture was cooled on ice. To this heat-denatured mRNA there were added 4 µl of 5 x first-strand buffer solution

EP 0 945 512 A2

(250 mM Tris/HCl, pH 8.3, 375 mM KCl, 15 mM MgCl₂), 1 µl of 10 mM dNTP, 2 µl of 0.1 M DTT, distilled water treated with DEPC and 5 µl (1000 U) of SuperScript II RT, and reaction was conducted at 37°C for one hour.

[0057] Next, 91 µl of distilled water treated with DEPC, 30 µl of 5 x second-strand buffer solution (100 mM Tris-HCl, pH 6.9, 450 mM KCl, 23 mM MgCl₂, 0.75 mM β-NAD⁺, 50 mM (NH₄)₂SO₄), 3 µl of 10 mM dNTP, 1 µl (10 U) of *E. coli* DNA ligase, 4 µl (40 U) of *E. coli* DNA polymerase and 1 µl (2 U) of *E. coli* RNase H were added to the reaction solution, and after reaction at 16°C for 2 hours, 2 µl (10 U) of T4 DNA polymerase was added and reaction was continued at 16°C for 5 minutes. A 10 µl portion of 0.5 M EDTA was added to and mixed with the solution, 150 µl of phenol:chloroform:isoamyl alcohol (25:24:1) was added, and after stirring the mixture it was centrifuged at 15,000 rpm for 5 minutes and the supernatant was recovered. To this supernatant there were added 10 µl of 5 M KOAc and 400 µl of ethanol, and the mixture was stirred and centrifuged at 15,000 rpm for 10 minutes. The precipitate was washed with 500 µl of 70% ethanol, lightly air dried and dissolved in 25 µl of distilled water treated with DEPC.

Step 2. Addition of adaptor for obtaining 5' end sequence

[0058] To 25 µl of the double-stranded cDNA obtained in step 1 there were added 10 µl of 5 x T4 DNA ligase buffer solution (250 mM Tris/HCl, pH 7.6, 50 mM MgCl₂, 5 mM ATP, 5 mM DTT, 25% (w/v) PEG 8000), 10 µl (10 µg) of a 5' RACE adaptor solution and 5 µl (5 U) of T4 DNA ligase, and after reaction at 16°C for 16 hours, 50 µl of phenol:chloroform:isoamyl alcohol (25:24:1) was added, the mixture was stirred and then centrifuged at 15,000 rpm for 5 minutes and the supernatant was recovered. To this supernatant there were added 5 µl of 5 M KOAc and 125 µl of ethanol, and after stirring the mixture and cooling it at -80°C for 20 minutes, it was centrifuged at 15,000 rpm for 10 minutes. The precipitate was washed with 200 µl of 70% ethanol, lightly air dried and then dissolved in 40 µl of distilled water treated with DEPC.

Step 3. Obtaining 5' end sequence and 3' end sequence

[0059] The antisense primer 5' ACCTTCTTAAGCGCCGCGTC 3' listed as SEQ. NO. 3 was synthesized based on the oligo dT primer sequence used in step 1 to obtain the 3' end sequence. Also, the primer 5' TCAGCCTGGCAGAT-CATTGC 3' shown in SEQ. ID. NO: 4 and the primer 5' CAGAAGTGACCGTCTCAGG 3' shown in SEQ. ID. NO: 5 which were specific to the sequences obtained in Example 1 were synthesized as sense primers. The sense primer 5' ACTCACTATAGGGCTCGAGCGGC 3' shown in SEQ. ID. NO: 6 was also synthesized based on the adaptor sequence added in step 2 to obtain the 5' end sequence.

[0060] The primer 5' ACAGGTATTCTTGCTCTGGG 3' shown in SEQ. NO. 7 and the primer 5' TTCTGTAGGCTGT-GGTCTCCC 3' which were specific to the sequences obtained in Example 1 were also synthesized as antisense primers. The cDNA obtained in step 1 was used as a template for PCR using the set of primers shown in SEQ. NO. 3 and 4 and the set of primers shown in SEQ. ID. NO: 6 and 7. The resulting PCR product was diluted 100-fold with TE solution and 0.5 µl of the dilution was used as a template for PCR using the set of primers listed as SEQ. NO. 3 and 5 and the set of primers listed as SEQ. NO. 6 and 8. The resulting PCR product was subcloned in a PCR II vector (Invitrogen Co.). The base sequence was determined according to a common method.

Example 3. Obtaining full length cDNA for novel serine proteases

[0061] The following primers were synthesized based on the sequences obtained in Example 2.

[0062] That is, the primer 5' GGATTCTGGAAGACCTCACCACC 3' shown in SEQ. ID. NO: 9 and the primer 5' CCATGGACGTCCCAGAGAGTTGTGAGTTTATTAAG 3' shown in SEQ. ID. NO: 10 were used as a set of primers for PCR with the single-stranded cDNA obtained in Example 1 as the template. The resulting product was subcloned in a pCR II vector (Invitrogen Co.). The base sequence was determined according to a common method.

[0063] As a result, the two types of cDNA shown in SEQ. ID. NO: 11 and 12 were obtained. The cDNA with a full length of 905 base pairs was designated as SP66 type 1, and the cDNA with a full length of 942 base pairs was designated as SP66 type 2. SP66 type 1 consists of a 54 bp 5' untranslated region, a 783 bp translated region and a 68 bp 3' untranslated region, and the translated region codes for a novel serine protease (260 amino acids). SP66 type 2 has a 918 bp translated region, and the translated region codes for a novel serine protease (305 amino acids). Also, SP66 type 1 and SP66 type 2 were shown to code for a common mature protein (mature serine protease) consisting of 228 amino acids.

Example 4. Assay of novel serine protease mature protein coded for by SP66 type 1 and SP66 type 2

(1) Construction of expression plasmid

[0064] A pUC18/SP66 type 1 DNA fragment and a pdKCR vector DNA fragment were ligated by a common method and used to transform *E. coli* JM109, and the resulting colonies were analyzed by PCR to obtain the target serine protease SP66 expression plasmid pdKCR/SP66. Next, cDNA coding for the signal sequence of trypsin II following the initiating methionine and for an enterokinase-recognizing sequence was amplified, and primers were designed with EcoRI added upstream of the 5' end and a BspMI restriction endonuclease-recognition site downstream of the 3' end. These primers were used for PCR with the pCR/Trypsin II plasmid as the template, and after digesting the product with restriction endonucleases (EcoRI and BspMI), an approximately 75 bp DNA fragment was isolated and purified. [0065] Similarly, a primer designed with a BspMI restriction endonuclease-recognition site added upstream of the DNA coding for the SP66 mature protein was used as a primer for PCR with pdKCR/SP66 as the template, and after digesting the product with restriction endonucleases (BspMI and Bpu 1102I), a DNA fragment was isolated and purified. Next, the obtained cDNA fragment coding for the signal sequence of trypsin II and for an enterokinase-recognizing sequence and a cDNA fragment coding for the SP66 mature protein were ligated with the pdKCR/SP66 vector which had been predigested with restriction endonucleases (BspMI and Bpu 1102I) and used to transform *E. coli* JM109. Colonies containing the target chimeric DNA among the transformed colonies were verified by PCR to obtain an expression plasmid (pdKCR/Trp66).

(2) Expression in COS-1 cells

[0066] The expression plasmid constructed in Example 4 (1) was used for transfection in COS-1 cells using lipofectin (Life Technologies). That is, 5×10^5 COS-1 cells were implanted in 10-cm diameter culturing dishes (Corning, 430167) with Dulbecco's minimum essential medium (DMEM, Nissui Seiyaku) containing 10% fetal bovine serum. On the following day, the cells were rinsed with 5 ml of Opti-MEM medium (Life Technologies), after which 5 ml of Opti-MEM medium was freshly added for culturing at 37°C for 2 hours.

[0067] After the culturing, a mixture of 1 µg of the aforementioned plasmid and 5 µg of lipofectin was added to each dish, and the culturing was continued at 37°C for 5 hours. After this culturing, 5 ml of Opti-MEM medium was added, for a total of 10 ml, and culturing was continued at 37°C for 72 hours. After this culturing, the culturing supernatant obtained by centrifugation was collected and used as the enzyme activity assay sample. As a control, a culture supernatant was prepared from transfection of the expression plasmid pdKCR alone into COS-1 cells.

(3) Measurement of enzyme activity

[0068] The enzyme activity in the culture supernatant obtained in Example 4 (2) was measured. That is, 5 µl of enterokinase (10 mg/ml, Biozyme Laboratories) was mixed with 45 µl of the COS-1 cell culture supernatant, and reacted at room temperature for 15 minutes. Next, 50 µl of a 0.2 M substrate solution containing the synthetic substrate Boc-Phe-Ser-Arg-MCA (Peptide Laboratories) dissolved in DMSO and diluted with 0.1 M Tris/HCl at pH 8.0 was added, and this was reacted at 37°C for one hour. After the reaction, the fluorescence was measured at an excitation wavelength of 485 nm and a fluorescent wavelength of 535 nm. As a result, enzyme activity was found only when the Trp66-expressing COS-1 cell culture supernatant was digested with enterokinase.

[0069] This result demonstrated that the serine protease encoded by SP66 is a functional protein with enzyme activity.

[0070] The novel serine proteases of the present invention carry out a specific role in the physiological functions of the brain through their enzyme function, and thus for the various neurodegenerative diseases where there is an imbalance between serine proteases and serine protease inhibitors in the brain, these serine proteases may be supplemented or expression of the serine proteases may be suppressed, in order to normalize the balance between the serine proteases and serine protease inhibitors in the brain, as an effective method of treatment.

[0071] As particular treatments there may be mentioned intraventricular administration and forced expression by gene therapy as supplementation treatments, which would be based on increasing intracerebral levels for improvement of dementia. Also possible are inhibition therapies based on inhibiting agents created by using the cDNA or a fragment described in the present application to express a gene recombinant and screening for inhibitors. The cDNA of the present application may also be applied in gene therapy using antisense inhibition methods since it is characterized by being human-derived.

[0072] Furthermore, monitoring the balance between serine proteases and serine protease inhibitors in the brain is important for diagnosis of various neurodegenerative diseases and pathological analysis, which includes biochemical examinations, and this can be accomplished by quantifying the amount of the novel serine proteases of the invention in body fluids, and especially the cerebrospinal fluid. For example, by measuring the amount of the novel serine pro-

EP 0 945 512 A2

teases of the invention in the cerebrospinal fluid it is possible to determine the amelioration or progression of dementia, and according to the invention there are also provided specific antibodies for the novel serine proteases of the invention and clinical examination kits for their measurement to determine therapeutic effects. In addition, since quantifying the amounts of the novel serine proteases of the invention in cerebrospinal fluid can serve to determine amelioration or progression of dementia, a major contribution is provided toward the development of drug treatments for diseases for which no method of treatment exist, such as Alzheimer's disease.

5

10

15

20

25

30

35

40

45

50

55

Annex to the description

[0073]

5

SEQUENCE LISTING

10

<110> SUNTORY LIMITED

<120> Novel serine proteases

15

<130> GPS/FP5755491

<140> EP 99301053.7

20

<141> 1999-02-15

<150> JP 10-031487

25

<151> 1998-02-13

<160> 14

30

<210> 1

<211> 20

<212> DNA

35

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

40

<220>

<221> misc_feature

<222> (9, 12)

45

<223> n is a or g or c or t

50

<400> 1

gtgctcacng cngcbcaytg

20

55

5 <210> 2
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 10 <220>
 <223> Description of Artificial Sequence: Primer

 <220>
 15 <221> misc_feature
 <222> (6, 9)
 <223> n is a or g or c or t

 20 <400> 2
 agcggncnc cdswrtcvcc 20

 25 <210> 3
 <211> 21
 <212> DNA
 <213> Artificial Sequence
 30
 <220>
 <223> Description of Artificial Sequence: Primer

 35 <400> 3
 accttcttaa gcgccggcgt c 21

 40 <210> 4
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 45
 <220>
 <223> Description of Artificial Sequence: Primer
 50
 <400> 4
 tcagcctggc agatcattgc 20

 55

EP 0 945 512 A2

5
 <210> 5
 <211> 20
 <212> DNA
 <213> Artificial Sequence

10
 <220>
 <223> Description of Artificial Sequence: Primer

15
 <400> 5
 cagaagtgca ccgtctcagg 20

20
 <210> 6
 <211> 23
 <212> DNA
 <213> Artificial Sequence

25
 <220>
 <223> Description of Artificial Sequence: Primer

30
 <400> 6
 actcactata gggctcgagc ggc 23

35
 <210> 7
 <211> 21
 <212> DNA
 <213> Artificial Sequence

40
 <220>
 <223> Description of Artificial Sequence: Primer

45
 <400> 7
 acagggtattt cttgctctgg g 21

50

55

```

5      <210>      8
      <211>      21
      <212>      DNA
      <213>      Artificial Sequence

10     <220>
      <223> Description of Artificial Sequence: Primer

15     <400>      8
      ttctgtaggc tgtggtctcc c                                21

20     <210>      9
      <211>      23
      <212>      DNA
      <213>      Artificial Sequence

25     <220>
      <223> Description of Artificial Sequence: Primer

30     <400>      9
      ggattctgga agacctcacc acc                                23

35     <210>      10
      <211>      35
      <212>      DNA
      <213>      Artificial Sequence

40     <220>
      <223> Description of Artificial Sequence: Primer

45     <400>      10
      ccatggacgt cccagagagt tgtgagttta ttaag                                35

50

```

EP 0 945 512 A2

<210> 11
 <211> 905
 <212> DNA
 <213> Homo sapiens

 <223> Nucleotide sequence of cDNA coding for a serine
 protease

 <400> 11

 cactgggtcc gaatcagtag gtgaccccgcc ccttggttc tggaagacct cacc atg 57
 Met
 1
 gga cgc ccc cga cct cgt gcg gcc aag acg tgg atg ttc ctg ctc ttg 105
 Gly Arg Pro Arg Pro Arg Ala Ala Lys Thr Trp Met Phe Leu Leu Leu
 5 10 15
 ctg ggg gga gcc tgg gca gga cac tcc agg gca cag gag gac aag gtg 153
 Leu Gly Gly Ala Trp Ala Gly His Ser Arg Ala Gln Glu Asp Lys Val
 20 25 30
 ctg ggg ggt cat gag tgc caa ccc cat tcg cag cct tgg cag gcg gcc 201
 Leu Gly Gly His Glu Cys Gln Pro His Ser Gln Pro Trp Gln Ala Ala
 35 40 45
 ttg ttc cag ggc cag caa cta ctc tgt ggc ggt gtc ctt gta ggt ggc 249
 Leu Phe Gln Gly Gln Gln Leu Leu Cys Gly Gly Val Leu Val Gly Gly
 50 55 60 65
 aac tgg gtc ctt aca gct gcc cac tgt aaa aaa ccg aaa tac aca gta 297
 Asn Trp Val Leu Thr Ala Ala His Cys Lys Lys Pro Lys Tyr Thr Val
 70 75 80
 cgc ctg gga gac cac agc cta cag aat aaa gat ggc cca gag caa gaa 345
 Arg Leu Gly Asp His Ser Leu Gln Asn Lys Asp Gly Pro Glu Gln Glu
 85 90 95
 ata cct gtg gtt cag tcc atc cca cac ccc tgc tac aac agc agc gat 393
 Ile Pro Val Val Gln Ser Ile Pro His Pro Cys Tyr Asn Ser Ser Asp
 100 105 110
 gtg gag gac cac aac cat gat ctg atg ctt ctt caa ctg cgt gac cag 441
 Val Glu Asp His Asn His Asp Leu Met Leu Leu Gln Leu Arg Asp Gln
 115 120 125

EP 0 945 512 A2

5 gca tcc ctg ggg tcc aaa gtg aag ccc atc agc ctg gca gat cat tgc 489
 Ala Ser Leu Gly Ser Lys Val Lys Pro Ile Ser Leu Ala Asp His Cys
 130 135 140 145
 acc cag cct ggc cag aag tgc acc gtc tca ggc tgg ggc act gtc acc 537
 10 Thr Gln Pro Gly Gln Lys Cys Thr Val Ser Gly Trp Gly Thr Val Thr
 150 155 160
 agt ccc cga gag aat ttt cct gac act ctc aac tgt gca gaa gta aaa 585
 Ser Pro Arg Glu Asn Phe Pro Asp Thr Leu Asn Cys Ala Glu Val Lys
 165 170 175
 atc ttt ccc cag aag aag tgt gag gat gct tac ccg ggg cag atc aca 633
 Ile Phe Pro Gln Lys Lys Cys Glu Asp Ala Tyr Pro Gly Gln Ile Thr
 180 185 190
 20 gat ggc atg gtc tgt gca ggc agc agc aaa ggg gct gac acg tgc cag 681
 Asp Gly Met Val Cys Ala Gly Ser Ser Lys Gly Ala Asp Thr Cys Gln
 195 200 205
 25 ggc gat tct gga ggc ccc ctg gtg tgt gat ggt gca ctc cag ggc atc 729
 Gly Asp Ser Gly Gly Pro Leu Val Cys Asp Gly Ala Leu Gln Gly Ile
 210 215 220 225
 aca tcc tgg ggc tca gac ccc tgt ggg agg tcc gac aaa cct ggc gtc 777
 30 Thr Ser Trp Gly Ser Asp Pro Cys Gly Arg Ser Asp Lys Pro Gly Val
 230 235 240
 tat acc aac atc tgc cgc tac ctg gac tgg atc aag aag atc ata ggc 825
 Tyr Thr Asn Ile Cys Arg Tyr Leu Asp Trp Ile Lys Lys Ile Ile Gly
 245 250 255
 35 agc aag ggc tgattctagg ataagcacta gatctccctt aataaactca caactct 881
 Ser Lys Gly
 40 260
 ctggaaaaaa aaaaaaaaaa aaaa 905

<210> 12

<211> 942

<212> DNA

<213> Homo sapiens

<223> Nucleotide sequence of cDNA coding for a serine
 protease

EP 0 945 512 A2

<400> 12

5 atg gga cgc ccc cga cct cgt gcg gcc aag acg tgg atg ttc ctg ctc 48
Met Gly Arg Pro Arg Pro Arg Ala Ala Lys Thr Trp Met Phe Leu Leu

1 5 10 15

10 ttg ctg ggg gga gcc tgg gca cgt gtg gaa gcc tgg acc tcc tca cta 96
Leu Leu Gly Gly Ala Trp Ala Ala Cys Gly Ser Leu Asp Leu Leu Thr

20 25 30

15 agg gac act cca ggg cac agg agg aca agg tgc tgg ggt tgt atg cgg 144
Lys Lys Tyr Ala Glu Asn Leu Pro Cys Val His Leu Asn Pro Gln Trp

35 40 45

20 aga act tgc cgt gtg tcc att tga acc cac agt ggc ctt ccc agc cct 192
Pro Ser Gln Pro Ser His Cys Pro Arg Gly Trp Arg Ser Asn Pro Leu

50 55 60

25 cgc act gcc cca gag ggt ggc gat cca acc ctc tcc ctc ctg ctg cag 240
Pro Pro Ala Ala Gly His Ser Arg Ala Gln Glu Asp Lys Val Leu Gly

65 70 75 80

30 ggt cat gag tgc caa ccc cat tcg cag cct tgg cag gcg gcc ttg ttc 288
Gly His Glu Cys Gln Pro His Ser Gln Pro Trp Gln Ala Ala Leu Phe

85 90 95

35 cag ggc cag caa cta ctc tgt ggc ggt gtc ctt gta ggt ggc aac tgg 336
Gln Gly Gln Gln Leu Leu Cys Gly Gly Val Leu Val Gly Gly Asn Trp

100 105 110

40 gtc ctt aca gct gcc cac tgt aaa aaa ccg aaa tac aca gta cgc ctg 384
Val Leu Thr Ala Ala His Cys Lys Lys Pro Lys Tyr Thr Val Arg Leu

115 120 125

45 gga gac cac agc cta cag aat aaa gat ggc cca gag caa gaa ata cct 432
Gly Asp His Ser Leu Gln Asn Lys Asp Gly Pro Glu Gln Glu Ile Pro

130 135 140

50 gtg gtt cag tcc atc cca cac ccc tgc tac aac agc agc gat gtg gag 480
Val Val Gln Ser Ile Pro His Pro Cys Tyr Asn Ser Ser Asp Val Glu

145 150 155 160

55 gac cac aac cat gat ctg atg ctt ctt caa ctg cgt gac cag gca tcc 528
Asp His Asn His Asp Leu Met Leu Leu Gln Leu Arg Asp Gln Ala Ser

165 170 175

ctg ggg tcc aaa gtg aag ccc atc agc ctg gca gat cat tgc acc cag 576
Leu Gly Ser Lys Val Lys Pro Ile Ser Leu Ala Asp His Cys Thr Gln

180 185 190

EP 0 945 512 A2

5 cct ggc cag aag tgc acc gtc tca ggc tgg ggc act gtc acc agt ccc 624
 Pro Gly Gln Lys Cys Thr Val Ser Gly Trp Gly Thr Val Thr Ser Pro
 195 200 205
 10 cga gag aat ttt cct gac act ctc aac tgt gca gaa gta aaa atc ttt 672
 Arg Glu Asn Phe Pro Asp Thr Leu Asn Cys Ala Glu Val Lys Ile Phe
 210 215 220
 15 ccc cag aag aag tgt gag gat gct tac ccg ggg cag atc aca gat ggc 720
 Pro Gln Lys Lys Cys Glu Asp Ala Tyr Pro Gly Gln Ile Thr Asp Gly
 225 230 235 240
 20 atg gtc tgt gca ggc agc agc aaa ggg gct gac acg tgc cag ggc gat 768
 Met Val Cys Ala Gly Ser Ser Lys Gly Ala Asp Thr Cys Gln Gly Asp
 245 250 255
 25 tct gga ggc ccc ctg gtg tgt gat ggt gca ctc cag ggc atc aca tcc 816
 Ser Gly Gly Pro Leu Val Cys Asp Gly Ala Leu Gln Gly Ile Thr Ser
 260 265 270
 30 tgg ggc tca gac ccc tgt ggg agg tcc gac aaa cct ggc gtc tat acc 864
 Trp Gly Ser Asp Pro Cys Gly Arg Ser Asp Lys Pro Gly Val Tyr Thr
 275 280 285
 35 aac atc tgc cgc tac ctg gac tgg atc aag aag atc ata ggc agc aag 912
 Asn Ile Cys Arg Tyr Leu Asp Trp Ile Lys Lys Ile Ile Gly Ser Lys
 290 295 300
 ggc tgattctagg ataagcacta gatctcc 942
 Gly
 40 305
 <210> 13
 <211> 260
 <212> PRT
 <213> Homo sapiens
 <223> Amino acid sequence of serine protease
 45 <400> 13
 Met Gly Arg Pro Arg Pro Arg Ala Ala Lys Thr Trp Met Phe Leu Leu
 1 5 10 15
 55

EP 0 945 512 A2

5	Leu Leu Gly Gly Ala Trp Ala Gly His Ser Arg Ala Gln Glu Asp Lys	20	25	30
10	Val Leu Gly Gly His Glu Cys Gln Pro His Ser Gln Pro Trp Gln Ala	35	40	45
15	Ala Leu Phe Gln Gly Gln Gln Leu Leu Cys Gly Gly Val Leu Val Gly	50	55	60
20	Gly Asn Trp Val Leu Thr Ala Ala His Cys Lys Lys Pro Lys Tyr Thr	65	70	75
25	Val Arg Leu Gly Asp His Ser Leu Gln Asn Lys Asp Gly Pro Glu Gln	85	90	95
30	Glu Ile Pro Val Val Gln Ser Ile Pro His Pro Cys Tyr Asn Ser Ser	100	105	110
35	Asp Val Glu Asp His Asn His Asp Leu Met Leu Leu Gln Leu Arg Asp	115	120	125
40	Gln Ala Ser Leu Gly Ser Lys Val Lys Pro Ile Ser Leu Ala Asp His	130	135	140
45	Cys Thr Gln Pro Gly Gln Lys Cys Thr Val Ser Gly Trp Gly Thr Val	145	150	155
50	Thr Ser Pro Arg Glu Asn Phe Pro Asp Thr Leu Asn Cys Ala Glu Val	165	170	175
55	Lys Ile Phe Pro Gln Lys Lys Cys Glu Asp Ala Tyr Pro Gly Gln Ile	180	185	190
	Thr Asp Gly Met Val Cys Ala Gly Ser Ser Lys Gly Ala Asp Thr Cys	195	200	205
	Gln Gly Asp Ser Gly Gly Pro Leu Val Cys Asp Gly Ala Leu Gln Gly	210	215	220

EP 0 945 512 A2

Ile Thr Ser Trp Gly Ser Asp Pro Cys Gly Arg Ser Asp Lys Pro Gly
 225 230 235 240
 Val Tyr Thr Asn Ile Cys Arg Tyr Leu Asp Trp Ile Lys Lys Ile Ile
 245 250 255
 Gly Ser Lys Gly
 260
 <210> 14
 <211> 305
 <212> PRT
 <213> Homo sapiens
 <223> Amino acid sequence of serine protease
 <400> 14
 Met Gly Arg Pro Arg Pro Arg Ala Ala Lys Thr Trp Met Phe Leu Leu
 1 5 10 15
 Leu Leu Gly Gly Ala Trp Ala Ala Cys Gly Ser Leu Asp Leu Leu Thr
 20 25 30
 Lys Lys Tyr Ala Glu Asn Leu Pro Cys Val His Leu Asn Pro Gln Trp
 35 35 40 45
 Pro Ser Gln Pro Ser His Cys Pro Arg Gly Trp Arg Ser Asn Pro Leu
 50 55 60
 Pro Pro Ala Ala Gly His Ser Arg Ala Gln Glu Asp Lys Val Leu Gly
 40 65 70 75 80
 Gly His Glu Cys Gln Pro His Ser Gln Pro Trp Gln Ala Ala Leu Phe
 85 90 95
 Gln Gly Gln Gln Leu Leu Cys Gly Gly Val Leu Val Gly Gly Asn Trp
 45 100 105 110
 Val Leu Thr Ala Ala His Cys Lys Lys Pro Lys Tyr Thr Val Arg Leu
 115 120 125
 Gly Asp His Ser Leu Gln Asn Lys Asp Gly Pro Glu Gln Glu Ile Pro
 50 130 135 140
 Val Val Gln Ser Ile Pro His Pro Cys Tyr Asn Ser Ser Asp Val Glu
 145 150 155 160

Asp His Asn His Asp Leu Met Leu Leu Gln Leu Arg Asp Gln Ala Ser
 5 165 170 175
 Leu Gly Ser Lys Val Lys Pro Ile Ser Leu Ala Asp His Cys Thr Gln
 180 185 190
 10 Pro Gly Gln Lys Cys Thr Val Ser Gly Trp Gly Thr Val Thr Ser Pro
 195 200 205
 Arg Glu Asn Phe Pro Asp Thr Leu Asn Cys Ala Glu Val Lys Ile Phe
 210 215 220
 15 Pro Gln Lys Lys Cys Glu Asp Ala Tyr Pro Gly Gln Ile Thr Asp Gly
 225 230 235 240
 Met Val Cys Ala Gly Ser Ser Lys Gly Ala Asp Thr Cys Gln Gly Asp
 245 250 255
 20 Ser Gly Gly Pro Leu Val Cys Asp Gly Ala Leu Gln Gly Ile Thr Ser
 260 265 270
 Trp Gly Ser Asp Pro Cys Gly Arg Ser Asp Lys Pro Gly Val Tyr Thr
 25 275 280 285
 Asn Ile Cys Arg Tyr Leu Asp Trp Ile Lys Lys Ile Ile Gly Ser Lys
 290 295 300
 30 Gly
 305

35 Claims

1. A polypeptide having the amino acid sequence shown in SEQ. ID. NO:13, or an amino acid sequence modified by deletion, addition, substitution or a combination thereof of one or more amino acids in said amino acid sequence and having serine protease activity; or a partial peptide thereof.
2. A polypeptide having the amino acid sequence shown in SEQ. ID. NO:14, or an amino acid sequence modified by deletion, addition, substitution or a combination thereof of one or more amino acids in said amino acid sequence and having serine protease activity; or a partial peptide thereof.
3. A polypeptide encoded by naturally occurring DNA which hybridizes with DNA having the nucleotide sequence shown in SEQ. ID. NO:11 under stringent conditions, which has serine protease activity.
4. A polypeptide encoded by naturally occurring DNA which hybridizes with DNA having the nucleotide sequence shown in SEQ. ID. NO:12 under stringent conditions, which has serine protease activity.
5. A polypeptide according to any one of claims 1 to 4, having an amino acid sequence with at least 70% homology with respect to the amino acid sequence shown in SEQ. ID. NO:13 or SEQ. ID. NO:14.
6. A polypeptide according to claim 5, having an amino acid sequence with at least 80% homology with respect to the amino acid sequence shown in SEQ. ID. NO:13 or SEQ. ID. NO:14.
7. A polypeptide according to claim 6, having an amino acid sequence with at least 90% homology with respect to the amino acid sequence shown in SEQ. ID. NO:13 or SEQ. ID. NO:14.

EP 0 945 512 A2

8. DNA coding for a polypeptide or partial peptide according to any one of claims 1 to 7, or a fragment thereof.
9. DNA according to claim 8 which suppresses expression of serine protease by the antisense method, or a fragment thereof.
- 5 10. A vector comprising DNA or a fragment according to claim 8 or 9.
11. A host transformed by an expression vector according to claim 10.
- 10 12. A method for producing a polypeptide or partial peptide according to any one of claims 1 to 7, characterized by culturing or breeding a host according to claim 11 and collecting the polypeptide or partial peptide thereof.
13. An antibody which recognize a polypeptide or partial peptide according to any one of claims 1 to 7.
- 15 14. A screening method for physiologically active substances, using a polypeptide or partial peptide according to any one of claims 1 to 7, or DNA or its fragment according to claim 8 or 9.

20

25

30

35

40

45

50

55